17 November 2018 : Clinical Research
A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective AnalysisJing Gong12ABCDEF, Ling Xu12ABCDEF, Zhi Li12AC, Xuejun Hu3B, Jing Liu12B, Yuee Teng12B, Bo Jin12B, Mingfang Zhao12B, Jing Shi12B, Tianshu Guo12BDEF, Xiaonan Shi12BCDF, Yu Cheng12EFG, Yunpeng Liu12AB*, Xiujuan Qu12AG
Med Sci Monit 2018; 24: CLR8264-8271
BACKGROUND: Although several complicated models have been built to evaluate the prognosis of NSCLC patients receiving chemotherapy, simple economic models are still needed to give a preliminary survival assessment of these patients.
MATERIAL AND METHODS: This study retrospectively assessed the clinical and biological parameters of 223 patients with advanced NSCLC. Univariate and multivariate analyses of overall survival (OS) and progression-free survival (PFS) for the parameters and the prognostic score were assessed.
RESULTS: Performance status (PS) score=1, smoking history, fibrinogenemia, thrombocytosis, increased lactate dehydrogenase (LDH) level, and anemia were independent predictors of poor prognosis in the univariate analysis of OS and were assessed in multivariate analysis. There was a significant difference in PS=1 (HR=2.134, p<0.0001), increased LDH level (HR=1.508, p=0.014), thrombocytosis (HR=1.547, p=0.012), and smoking history (HR=1.491, p=0.008), based on which the patients were classified into 3 risk groups: low risk (0–1 points), moderate risk (2 points), and high risk (3–5 points). At p values of <0.0001, the median OS was 565, 340, and 273 days and the median progression-free survival was 250, 209, and 135 days, respectively in these 3 risk groups.
CONCLUSIONS: We established a new prognostic score model using PS, LDH level, PLT count, and smoking history to predict the survival of patients receiving first-line chemotherapy for advanced NSCLC, which might be useful in clinical practice.
Keywords: Lung Neoplasms, Overall, Prognosis, Survival
25 October 2021 : EditorialEditorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD)
Med Sci Monit 2021; 27:e935172
22 October 2021 : Clinical ResearchA Novel Method for the Production of an Autologous Anti-Inflammatory and Anti-Catabolic Product (Cytorich) ...
Med Sci Monit In Press; DOI: 10.12659/MSM.934365
11 October 2021 : Clinical ResearchClinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia:...
Med Sci Monit In Press; DOI: 10.12659/MSM.933381
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
27 Oct 2021 : Clinical ResearchUse of the Braden Scale to Predict Injury Severity in Mass Burn Casualties
Med Sci Monit In Press; DOI: 10.12659/MSM.934039
27 Oct 2021 : Database AnalysisLow Expression of Long Noncoding RNA SLC26A4 Antisense RNA 1 Is an Independent Prognostic Biomarker and Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934522
27 Oct 2021 : Database AnalysisA Novel Predictive Model Incorporating Ferroptosis-Related Gene Signatures for Overall Survival in Patients...
Med Sci Monit In Press; DOI: 10.12659/MSM.934050
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700